Modulating TLS in Cancer Immunotherapy: Recent Advances

Hosted by Alban Bessede, PhD, CEO of Explicyte Immuno-Oncology, this 45-minute webinar will feature 2 presentations, followed by questions:

Tertiary lymphoid structures as modulators of anti-tumor immunity: what do we know and where are we headed?

Tullia C. Bruno, PhD - UPMC Hillman Cancer Center / University of Pittsburgh

Following a PhD thesis on intratumoral T cells at Johns Hopkins in 2010, Tullia Bruno started working on the role of B cells in the TME during her postdoctoral fellowship at the University of Colorado Denver. In 2015, she joined the University of Pittsburgh as an Assistant Professor to investigate the role of intratumoral B cell function within TLS in solid tumors. Focused on translational research and the development of novel immunotherapies, she is also a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center.

Predictive role of TLS for cancer immunotherapy: current insights and perspectives

Pr. Antoine Italiano, MD, PhD - Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers

Author of 500+ peer-reviewed publications, Pr. Italiano has been the Principal Investigator of 50+ clinical trials over the past 5 years, investigating the resistance mechanisms to cancer immunotherapies in solid tumors. Trained as a medical oncologist in France, he obtained a PhD in Molecular & Cell Biology in 2008. He then joined the laboratory of Cristina Antonescu for a post-doctoral fellowship at the MSKCC (New York, USA). He is currently leading Early Phase Trials and Sarcoma Units at Institut Bergonié (Bordeaux, France) and the head of the Precision Medicine unit at Gustave Roussy (Villejuif, France).

> More about TLS detection & scoring in patient specimens